Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Assets (2016 - 2026)

Ironwood Pharmaceuticals' Assets history spans 16 years, with the latest figure at $396.9 million for Q4 2025.

  • On a quarterly basis, Assets rose 13.11% to $396.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $396.9 million, a 13.11% increase, with the full-year FY2025 number at $396.9 million, up 13.11% from a year prior.
  • Assets hit $396.9 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $396.1 million in the prior quarter.
  • Over the last five years, Assets for IRWD hit a ceiling of $1.2 billion in Q1 2023 and a floor of $327.2 million in Q1 2025.
  • Historically, Assets has averaged $690.2 million across 5 years, with a median of $561.7 million in 2021.
  • Biggest five-year swings in Assets: soared 127.09% in 2021 and later plummeted 62.02% in 2024.
  • Tracing IRWD's Assets over 5 years: stood at $1.1 billion in 2021, then fell by 2.34% to $1.1 billion in 2022, then plummeted by 57.2% to $471.1 million in 2023, then fell by 25.51% to $350.9 million in 2024, then increased by 13.11% to $396.9 million in 2025.
  • Business Quant data shows Assets for IRWD at $396.9 million in Q4 2025, $396.1 million in Q3 2025, and $342.9 million in Q2 2025.